Skip to main content

What the FDA labels say about taking them together

Flurazepam and fosamprenavir

Fosamprenavir's FDA label of September 15, 2023 names flurazepam in its drug interactions section; the flurazepam label PlainMeds reads does not name fosamprenavir. The fosamprenavir label: “Clinical significance is unknown. A decrease in benzodiazepine dose may be needed.”

Check it at the source: the flurazepam FDA label on DailyMed (effective October 28, 2024, Chartwell RX, LLC); the fosamprenavir FDA label on DailyMed (effective September 15, 2023, Mylan Pharmaceuticals Inc.).

What does the flurazepam label say about fosamprenavir?

Flurazepam's label (effective October 28, 2024) does not name fosamprenavir in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Flurazepam Hydrochloride), Chartwell RX, LLC, effective October 28, 2024 (SPL set 8f476891-1346-4e8c-ac1b-f8cbdc64f5a1), via openFDA; the full label on DailyMed

What does the fosamprenavir label say about flurazepam?

Fosamprenavir label, drug interactions

Concomitant Drug Class/Drug Name: Benzodiazepines: Alprazolam, clorazepate, diazepam, flurazepam; Effect on Concentration of Amprenavir or Concomitant Drug: ↑ Benzodiazepines; Clinical Comment: Clinical significance is unknown. A decrease in benzodiazepine dose may be needed.

Source: FDA drug label (Fosamprenavir Calcium), Mylan Pharmaceuticals Inc., effective September 15, 2023 (SPL set 3a1424d8-844c-4e24-9ebd-b2c2b61b61a3), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

1Flurazepam generic labelers
2Fosamprenavir generic labelers
FlurazepamFosamprenavir
Labeled forInsomniaHIV
Boxed warningYesNo
Pharmacy cost (NADAC)n/an/a
Shortage nowIn shortageNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?